Vivani Medical, Inc. (NASDAQ:VANI) Financings

Vivani Medical, Inc.

Financings

RaiseDate
Private placement of common stock
Announced: about US$5.1M · US$1.01 a share
Buyers: Gregg Williams; Aaron Mendelsohn
Insiders: Purchased by Chairman Gregg Williams and director Aaron Mendelsohn
Use of proceeds: Research and clinical development of NPM-139 semaglutide implant and other candidates, working capital and general corporate purposes
Nov 16, 2026
Registered direct offering of shares of common stock
Closed: US$1.48 a share · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: Research and clinical development of product candidates, working capital and general corporate purposes
Jan 27, 2026
Private placement of shares of common stock
Closed: US$1.48 a share
Buyers: Gregg Williams (1,351,351 shares of common stock at $1.48 per share)
Insiders: All shares purchased by Gregg Williams, Chairman of the board
Use of proceeds: Research and clinical development of product candidates, working capital and general corporate purposes
Jan 27, 2026
Private placement of shares of common stock
Announced: about US$10M · US$1.26 a share
Buyers: entity beneficially owned by Gregg Williams
Insiders: Two investors including an entity beneficially owned by Chairman Gregg Williams
Use of proceeds: Secure financial position into second half of 2026 and accelerate development of NPM-139 into clinical-stage development
Aug 13, 2025
Private placement of shares
Update: about US$3M · US$1.03 a share
May 13, 2025
Private placement of shares
Announced: about US$8.25M · US$1.12 a share
Buyers: Entity beneficially owned by Gregg Williams
Insiders: The Company has entered into a securities purchase agreement with an entity beneficially owned by Gregg Williams, the Chairman of the board
Use of proceeds: Extend cash runway into Q2 2026; accelerate development of NPM-139 semaglutide implant and continue development of NPM-115
Mar 27, 2025

Read by 6ix AI from the company's releases